Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome profile Carnegie Stage 22 gut of different RET haplotypes

ABSTRACT: Transcriptome profile Carnegie Stage 22 gut of different RET haplotypes

PROVIDER: PRJNA436716 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6798410_1.fastq.gz	Fastqsanger.gz
	SRR6798410_2.fastq.gz	Fastqsanger.gz
	SRR6798411_1.fastq.gz	Fastqsanger.gz
	SRR6798411_2.fastq.gz	Fastqsanger.gz
	SRR6798412_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Transcriptome profile Carnegie Stage 22 gut of different RET haplotypes

Project description:Total mRNA seq was perfomed on human fetal gut tissue at CS22 on 3 samples having different RET haplotype which progressively reduce expression of RET. R haplotypes are resistant and S haplotypes are susceptible to Hirschsprung disease

2018-10-30 | GSE111341 | GEO

Primate Primordial Germ Cells Acquire Transplantation Potential by Carnegie Stage 23

Project description:Primate Primordial Germ Cells Acquire Transplantation Potential by Carnegie Stage 23

| PRJNA378239 | ENA

Gene expression repertoire of the human fetal gut and its effect due to HSCR associated polymorphisms

Project description:This is a gene expression study of human fetal gut at Carnegie stage (CS) 14 and CS22 classsfied by their HSCR associated enhancer haplotypes

2023-08-16 | GSE160359 | GEO

Ret

Project description:Drosophila melanogaster Ret, Ret oncogene, is differentially expressed in 13 experiment(s);

| FBgn0011829 | ExpressionAtlas

Ret

Project description:Drosophila melanogaster Ret, Ret oncogene, is expressed in 3 baseline experiment(s);

| FBgn0011829 | ExpressionAtlas

RNA-seq of RET-aberrant cancer cell lines treated with RET-TKI selpercatinib

Project description:RET-aberrant cancer discovered as a relevant targetable oncogene in several types of tumors, whose inhibitors have marked efficacy. However, some of patients with RET-aberrant cancer are insensitive to RET- tyrosine kinase inhibitors (TKIs) and are clinically non-responders. Recently, drug-tolerant mechanisms have been gaining attention as targets for initial therapies aimed at overcoming drug resistance. However, the underlying mechanisms of drug-tolerant cells emergence treated with RET-TKIs derived from RET-aberrant cancer cells remains unknown. In this study, HER3 signal activity through YAP1 was led to maintaining cell survival and inducing the emergence of cells tolerant to RET-TKIs selpercatinib and pralsetinib in high YAP1 expressed RET- rearranged cancer cells. These results suggested that YAP1-HER3 axis plays pivotal roles for cell survival under an exposure with RET-TKIs in the intrinsic resistance to RET-TKIs and the emergence of tolerant cells by RET-TKIs in YAP1 expressed RET-aberrant cancer, suggesting that YAP1/HER3 inhibition and RET-TKIs is a highly potent combination for initial treatment.

2024-09-30 | GSE261830 | GEO

Rhodosporidium toruloides haplotypes IFO0559 and IFO0880 rapamycin treatment

Project description:Comparison between control groups and rapamycin treatment of both haplotypes of Rhodosporidium toruloides.

2025-05-07 | PXD052386 | Pride

RET fusion genes, BCR-RET and FGFR1OP-RET, are associated with chronic myelomonocytic leukemia, display sensitivity to Sorafenib, an inhibitor of tyrosine-kinase activity and enhance monocytic differentiation

Project description:Myeloproliferative neoplasms are frequently associated with aberrant constitutive tyrosine kinase (TK) activity resulting from point mutations or chimaeric fusion genes, such as BCR ABL1 or JAK2 V617F. We report here for the first time in hematological malignancies, two novel fusion genes involving the TK RET, BCR-RET and FGFR1OP-RET, in chronic myelo monocytic leukemia (CMML) cases. The two RET fusion genes lead to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage. We also report that the BCR-RET fusion protein is insensitive to Imatinib but sensitive to Sorafenib in vivo. CMML is an hematopoietic malignancy associated with the frequent activation of the RAS pathway. The RET fusion genes seems to constitutively mimic the same signaling pathway than RAS mutations. Overall, the RET fusion genes behaviors in the monocytic lineage underlie the role of the normal RET TK activity during the physiological monocytic differentiation. We analysed BAF/3 cells infected by BCR-RET, FGFR1OP-RET or BCR-ABL1P210 fusion genes retroviruses and sorted out using EGFP fluorescence, with Affymetrix GeneChip MouseGene 1.0 ST platform.

2012-01-06 | E-GEOD-34900 | biostudies-arrayexpress

Ret

Project description:Rattus norvegicus Ret, ret proto-oncogene [Source:RGD Symbol;Acc:3556], is differentially expressed in 15 experiment(s);

| ENSRNOG00000014751 | ExpressionAtlas

Ret

Project description:Rattus norvegicus Ret, ret proto-oncogene [Source:RGD Symbol;Acc:3556], is expressed in 5 baseline experiment(s);

| ENSRNOG00000014751 | ExpressionAtlas